New chemotherapy agents for small cell lung cancer

Chest

Volumn 117, Issue 4 SUPPL. 1, 2000, Pages 156S-162S

  Kelly, Karen ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Cisplatin; Gemcitabine; Small cell lung cancer; Survival; Taxanes; Topotecan; Vinorelbine

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; TOPOTECAN; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; UNITED STATES;

EID: 0033996043     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.4_suppl_1.156S     Document Type: Conference Paper

References (44)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics 1998. CA Cancer J Clin 1998; 48:6-29
2. Sandler AB. Current management of small cell lung cancer. Semin Oncol 1997; 24:463-476
3. Bunn PA, Carney DN. Overview of chemotherapy for small cell lung cancer. Semin Oncol 1997; 24(suppl7):S69-S74
4. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282-291
5. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 1991; 83:855-861
6. Bunn PA Jr. Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 1989; 16:27-33
7. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin versus etoposide-carboplatin and irradiation in small cell lung cancer: a Hellenic Cooperative Oncology Group study. Ann Oncol 1994; 5:601-607
8. Rowinsky EK, Grochow LB, Hendricks CB, et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992; 10:647-656
9. Schiller JH, Kim KM, Hufson P, et al. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1996; 14:2345-2352
10. Watanabe K, Fukuoka M, Niitani H, for the Topotecan Lung Cancer Cooperative Study Group, Japan. Phase II trial of topotecan for small cell lung cancer (SCLC) [abstract 222]. Lung Cancer 1997; 18(suppl1):58
11. Depierre A, von Pawel J, Hans K, et al. Evaluation of topotecan (Hycamtinô) in relapsed small cell lung cancer (SCLC): a multicentre phase II study [abstract 126], Lung Cancer 1997; 18(suppl1):35
12. Ardizzoni A, Hansen H, Dombernowsky P, et al, for the European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15:2090-2096
13. Perez-Soler R, Glisson BS, Lee JS, et al. Phase II study of topotecan in patients with small cell lung cancer (SCLC) refractory to etoposide [abstract 1078]. Proc Am Soc Clin Oncol 1995; 14:355
14. Schiller JH, von Pawel J, Clarke P, et al. Preliminary results of a randomized comparative phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC) [abstract 41]. Lung Cancer 1997; 18(suppl1):13-14
15. Ettinger DS, Finkelstein DM, Sarma RP, et al. Phase II study of paclitaxel in patients with extensive disease small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1995; 13:1430-1435
16. Kirschling RJ, Jung SH, Jett JR, et al, for the North Central Cancer Treatment Group. A phase II trial of taxol and GCSF in previously untreated patients with extensive stage small cell lung cancer (SCLC) [abstract 1076], Proc Am Soc Clin Oncol 1994; 13:326
17. Nair S, Marschke R, Grill J, et al. A phase II study of paclitaxel (Taxol®) and cisplatin (CDDP) in the treatment of extensive stage small cell lung cancer (ESSCLC) [abstract 1629]. Proc Am Soc Clin Oncol 1997; 16:454A
18. Georgiadis MS, Brown JE, Schuler BS, et al. Phase I study of a four day continuous infusion of paclitaxel followed by cisplatin in patients with advanced lung cancer [abstract 1072]. Proc Am Soc Clin Oncol 1995; 14:353
19. Kelly K, Wood ME, Bunn PA Jr. A phase I study of cisplatin, etoposide, and paclitaxel (PET) in small cell lung cancer (SCLC) [abstract 97]. Lung Cancer 1997; 18(suppl1):28
20. Glisson BS, Kurie JM, Fox NJ, et al. Phase I-II study of cisplatin, etoposide, and paclitaxel (PET) in patients with extensive small cell lung cancer (ESCLC) [abstract 1635]. Proc Am Soc Clin Oncol 1997; 16:455A
21. Levitan N, McKenney J, Tahsildar H, et al. Results of a phase I dose escalation trial of paclitaxel, etoposide, and cisplatin followed by filgrastim in the treatment of patients with extensive stage small cell lung cancer [abstract 1177]. Proc Am Soc Clin Oncol 1995; 14:379
22. Bremnes RM, Sundstrom S, Aasebo U, et al. Treatment of limited small cell lung cancer (SCLC) with paclitaxel, cisplatin, etoposide and radiation therapy [abstract 206]. Lung Cancer 1997; 18(suppl1):54
23. Hainsworth JD, Gray JR, Stroup S, et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J Clin Oncol 1997; 15:3464-3470
24. Neill HB, Miller AA, Clamon GH, et al. A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. Semin Oncol 1997; 24(suppl12):S130-S134
25. Gatzemeier U, Jagos U, Kaukel E, et al. Paclitaxel, carboplatin and oral etoposide: a phase II trial in limited-stage small cell lung cancer. Semin Oncol 1997; 24(suppl12):S149-S152
26. Jett JR, Day R, Levitt M, et al. Topotecan and paclitaxel in extensive stage small cell lung cancer (ED-SCLC) patients without prior therapy [abstract 28]. Lung Cancer 1997; 18(suppl 1):13
27. Strauss GM, Lynch TJ, Elias AD, et al. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. Semin Oncol 1997; 24(suppl12): S73-S80
28. Perez EA. Phase II study and pharmacokinetics of oral etoposide and intravenous paclitaxel in extensive stage small cell lung cancer: an NCCTG study [abstract 53]. Lung Cancer 1997; 18(suppl 1):17
29. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer 1994; 30A:1058-1060
30. Burris HA, Crowley SJ, Williamson SK, et al. Docetaxel (Taxotere) in extensive stage small cell lung cancer (SCLC): a phase II trial of the Southwest Oncology Group [abstract]. Proc Am Soc Clin Oncol 1998; 17:451
31. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1994; 5:283-285
32. Abratt RP, Bezwoda WR, Goedhals L, et al. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997; 15:744-749
33. Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997; 15:297-303
34. Depierre A, Le Chevalier T, Quoix E, et al. Phase II trial of navelbine (NVB) in small cell lung cancer (SCLC) [abstract 1]. Lung Cancer 1997; 18(suppl 1):3
35. Tummarello D, Graziano F, Giodani P. A phase II study of vinorelbine (VNB) in small cell lung cancer (SCLC) patients (PTS) unsuitable for standard chemotherapy (CHT) [abstract 1137]. Proc Am Soc Clin Oncol 1995; 14:369
36. Furuse K, Fukuoka M, Kimura I, et al. Early phase II study of vinorelbine (VRB) in small cell lung (SCLC) [abstract 1143]. Proc Am Soc Clin Oncol 1995; 14:371
37. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 1993; 29A:1720-1722
38. Lake D, Johnson E, Herndon J, et al. Phase II trial of Navelbine® (NVB) in relapsed small cell lung cancer (SCLC) [abstract 1703]. Proc Am Soc Clin Oncol 1997; 16:473A
39. Richardet E, Carranza L, Uribe A, et al. Phase II study: cisplatin (C) + etoposide (E) + navelbine (N) in small cell lung cancer (SCLC) [abstract 1151]. Proc Am Soc Clin Oncol 1995; 14:373
40. Gridelli C, Ianniello G, Brancaccio L, et al. Carboplatin plus vinorelbine: a new active regimen in extensive small cell lung cancer: results of a multicenter phase II study [abstract 212]. Lung Cancer 1997; 18(suppl 1):55
41. Negoro S, Fukuoka M, Niitani H, et al. A phase II study of CPT-11, a camptothecin derivative in patients with primary lung cancer. Gan To Kagaku Ryoho (Jpn J Cancer Chemother) 1991; 18:1013-1019
42. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10:1225-1229
43. Le Chevalier T, Ibrahim N, Chorny P, et al. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT) [abstract 1617]. Proc Am Soc Clin Oncol 1997; 16:450A
44. Brown P. Matrix metalloproteinase inhibitors: a new class of anticancer agent. Curr Opin Invest Drugs 1993; 2:617-626